International AIDS Society global scientific strategy: Towards an HIV cure 2016

Nature Medicine

Volumn 22, Issue 8, 2016, Pages 839-850

  Deeks, Steven G ^a   Lewin, Sharon R ^b,c   Ross, Anna Laura ^d   Ananworanich, Jintanat ^e,f   Benkirane, Monsef ^g   Cannon, Paula ^h   Chomont, Nicolas ⁱ   Douek, Daniel ^j   Lifson, Jeffrey D ^k   Lo, Ying Ru ^l   Kuritzkes, Daniel ^m   Margolis, David ⁿ   Mellors, John ^o   Persaud, Deborah ^p   Tucker, Joseph D ^q   Barre Sinoussi, Françoise ^r   Alter, Galit ^s   Auerbach, Judith ^a   Autran, Brigitte ^t,u,v   Barouch, Dan H ^s,w   Behrens, Georg ^x   Cavazzana, Marina ^y   Chen, Zhiwei ^z   Cohen, Éric A ^aa   Corbelli, Giulio Maria ^ab   Eholié, Serge ^ac   Eyal, Nir ^ad   Fidler, Sarah ^ae   Garcia, Laurindo ^af   Grossman, Cynthia ^ag   Henderson, Gail ⁿ   Henrich, Timothy J ^a,m   Jefferys, Richard ^ah   Kiem, Hans Peter ^ai   McCune, Joseph ^a   Moodley, Keymanthri ^aj   Newman, Peter A ^ak   Nijhuis, Monique ^al   Nsubuga, Moses Supercharger ^am   Ott, Melanie ^an   Palmer, Sarah ^ao   Richman, Douglas ^ap   Saez Cirion, Asier ^r   Sharp, Matthew ^aq   Siliciano, Janet ^p   Silvestri, Guido ^ar   Singh, Jerome ^as   Spire, Bruno ^at   Taylor, Jeffrey ^au   Tolstrup, Martin ^av   Valente, Susana ^aw   Van Lunzen, Jan ^ax   Walensky, Rochelle ^ay   Wilson, Ira ^az   Zack, Jerome ^ba   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d ANRS   (France)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^g UNIV MONTPELLIER   (France)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF NORTH CAROLINA PROJECT CHINA   (China)

^r INSTITUT PASTEUR   (France)

^s MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^t Assistance publique Hôpitaux de Paris   (France)

^u INSERM   (France)

^v PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^w HARVARD MEDICAL SCHOOL   (United States)

^x HANNOVER MEDICAL SCHOOL   (Germany)

^y HÔPITAL NECKER ENFANTS MALADES   (France)

^z UNIVERSITY OF HONG KONG   (Hong Kong)

^aa CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^ab EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^ac CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^ad HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ae IMPERIAL COLLEGE LONDON   (United Kingdom)

^af B Change Group   (Philippines)

^ag NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^ah Treatment Action Group   (United States)

^ai Fred Hutchinson Cancer Research Center   (United States)

^aj STELLENBOSCH UNIVERSITY   (South Africa)

^ak UNIVERSITY OF TORONTO   (Canada)

^al UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^am JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^an UNIVERSITY OF CALIFORNIA   (United States)

^ao UNIVERSITY OF SYDNEY   (Australia)

^ap UNIVERSITY OF CALIFORNIA   (United States)

^aq Independent HIV Education and Advocacy Consultant   (United States)

^ar EMORY UNIVERSITY   (United States)

^as UNIVERSITY OF KWAZULU NATAL   (South Africa)

^at AIX MARSEILLE UNIV   (France)

^au CARE Collaboratory Community Advisory Board   (United States)

^av AARHUS UNIVERSITY   (Denmark)

^aw SCRIPPS RESEARCH INSTITUTE   (United States)

^ax VIIV HEALTHCARE   (United States)

^ay MASSACHUSETTS GENERAL HOSPITAL   (United States)

^az BROWN UNIVERSITY   (United States)

^ba UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL ENGINEERING; CELL THERAPY; COHORT ANALYSIS; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; IN VITRO STUDY; LATENT PERIOD; LYMPHOCYTE SUBPOPULATION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; REMISSION; REVIEW; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV INFECTIONS; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; MOTIVATION; ORGANIZATION; RESEARCH;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GOALS; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; ORGANIZATIONAL OBJECTIVES; RESEARCH; SOCIETIES, MEDICAL;

EID: 84978120368     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4108     Document Type: Review

References (126)

1. UN Joint Programme on HIV/AIDS (UNAIDS). The Gap Report, 2014; available at: http://www.refworld.org/docid/53f1e1604.html (accessed 23 April 2015).
2. Barré-Sinoussi, F., Ross, A.L. & Delfraissy, J.F. Past, present and future: 30 years of HIV research. Nat. Rev. Microbiol. 11, 877-883 (2013).
3. Deeks, S.G. et al. International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614 (2012).
4. Van Lint, C., Emiliani, S., Ott, M. & Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996).
5. Coull, J.J. et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74, 6790-6799 (2000).
6. + cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425-6437 (2010).
7. Han, Y. et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4, 134-146 (2008).
8. Ho, Y.C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
9. Buzón, M.J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460-465 (2010).
10. Hatano, H. et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J. Infect. Dis. 208, 1436-1442 (2013).
11. Fletcher, C.V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 111, 2307-2312 (2014).
12. Lorenzo-Redondol, R. et al. Persistent HIV-1 replication maintains the HIV-1 reservoir during therapy. Nature (in the press).
13. Kearney, M.F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).
14. Josefsson, L. et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. USA 110, E4987-E4996 (2013).
15. Archin, N.M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
16. Søgaard, O.S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
17. Elliott, J.H. et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520-e529 (2015).
18. Rasmussen, T.A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13-e21 (2014).
19. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501 (2012).
20. + T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013).
21. Laird, G.M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 125, 1901-1912 (2015).
22. Elliott, J.H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
23. + T cell depletion. J. Clin. Immunol. 21, 218-226 (2001).
24. Bui, J.K., Mellors, J.W. & Cillo, A.R. HIV-1 virion production from single inducible proviruses following T-cell activation ex vivo. J. Virol. 90, 1673-1676 (2015).
25. Vandergeeten, C. et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121, 4321-4329 (2013).
26. Jones, R.B. et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 10, e1004287 (2014).
27. Mousseau, G., Mediouni, S. & Valente, S.T. Targeting HIV transcription: the quest for a functional cure. Curr. Top. Microbiol. Immunol. 389, 121-145 (2015).
28. Mousseau, G. et al. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. MBio 6, e00465 (2015).
29. Barouch, D.H. & Deeks, S.G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169-174 (2014).
30. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900 (2009).
31. Yukl, S.A. et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J. Infect. Dis. 208, 1212-1220 (2013).
32. + T cells and can induce remission. J. Antimicrob. Chemother. 70, 2108-2120 (2015).
33. + T cells with stem cell-like properties. Nat. Med. 20, 139-142 (2014).
34. Connick, E. et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J. Immunol. 178, 6975-6983 (2007).
35. Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132-139 (2015).
36. Banga, R. et al. PD-1 and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. http://dx.doi.org/10.1038/nm.4113 (2016).
37. Calantone, N. et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity 41, 493-502 (2014).
38. Churchill, M.J., Cowley, D.J., Wesselingh, S.L., Gorry, P.R. & Gray, L.R. HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research. J. Neurovirol. 21, 290-300 (2015).
39. Honeycutt, J.B. et al. Macrophages sustain HIV replication in vivo independently of T cells. J. Clin. Invest. 126, 1353-1366 (2016).
40. Wagner, T.A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570-573 (2014).
41. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179-183 (2014).
42. + T cells determined by replication-incompetent integrated HIV-1 provirus. AIDS 28, 1091-1099 (2014).
43. + T cells can produce infectious HIV-1 in vivo. Proc. Natl. Acad. Sci. USA 113, 1883-1888 (2016).
44. + T cells. PLoS Pathog. 9, e1003799 (2013).
45. Casazza, J.P. et al. VRC 101 Study Team. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829-1840 (2013).
46. + T cell epitope recognition paradigms. Science 340, 1237874 (2013).
47. Hansen, S.G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
48. + T cell responses restricted by major histocompatibility complex E. Science 351, 714-720 (2016).
49. Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014).
50. Barouch, D.H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
51. Lynch, R.M. et al. VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
52. Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
53. Chun, T.W. et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc. Natl. Acad. Sci. USA 111, 13151-13156 (2014).
54. Euler, Z. & Alter, G. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res. Hum. Retroviruses 31, 13-24 (2015).
55. Pegu, A. et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat. Commun. 6, 8447 (2015).
56. Sung, J.A. et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077-4090 (2015).
57. Micci, L. et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J. Clin. Invest. 125, 4497-4513 (2015).
58. Henrich, T.J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319-327 (2014).
59. Stock, P.G. et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am. J. Transplant. 14, 1136-1141 (2014).
60. Wightman, F. et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS 29, 504-506 (2015).
61. International HIV Controllers Study. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551-1557 (2010).
62. Sáez-Cirión, A. et al. ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
63. Frange, P. et al. ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49-e54 (2016).
64. Whitney, J.B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74-77 (2014).
65. Denton, P.W. et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014).
66. Del Prete, G.Q. et al. Elevated plasma viral loads in romidepsin-treated simian immunodeficiency virus-infected rhesus macaques on suppressive combination antiretroviral therapy. Antimicrob. Agents Chemother. 60, 1560-1572 (2015).
67. Marsden, M.D. et al. HIV latency in the humanized BLT mouse. J. Virol. 86, 339-347 (2012).
68. Persaud, D. et al. Pediatric HIV/AIDS Cohort Study. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 168, 1138-1146 (2014).
69. Ananworanich, J. et al. HIV-NAT 194 Study Group. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 28, 1015-1020 (2014).
70. Uprety, P. et al. Cell-associated HIV-1 DNA and RNA decay dynamics during early combination antiretroviral therapy in HIV-1-infected infants. Clin. Infect. Dis. 61, 1862-1870 (2015).
71. Muenchhoff, M., Prendergast, A.J. & Goulder, P.J. Immunity to HIV in early life. Front. Immunol. 5, 391 (2014).
72. Hütter, G. et al. Long-term control of HIV by CCR5 Δ32/Δ32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
73. Cannon, P. & June, C. Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 6, 74-79 (2011).
74. + cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).
75. + T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122, 179-187 (2013).
76. Hu, W. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111, 11461-11466 (2014).
77. Kitchen, S.G. et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 8, e1002649 (2012).
78. Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
79. Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
80. Balazs, A.B. et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20, 296-300 (2014).
81. Gardner, M.R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87-91 (2015).
82. Smith, D.J. et al. Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells. Proc. Natl. Acad. Sci. USA 112, 1523-1528 (2015).
83. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
84. Beard, B.C. et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Invest. 120, 2345-2354 (2010).
85. Laird, G.M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
86. Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555 (2005).
87. Crooks, A.M. et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 212, 1361-1365 (2015).
88. + T cells from patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 111, 7078-7083 (2014).
89. Procopio, F.A. et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine 2, 872-881 (2015).
90. Metcalf Pate, K.A. et al. A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads. J. Infect. Dis. 212, 1387-1396 (2015).
91. Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).
92. Burbelo, P.D. et al. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J. Infect. Dis. 209, 1613-1617 (2014).
93. Williams, J.P. et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 3, e03821 (2014).
94. Li, J.Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343-353 (2016).
95. Persaud, D. & Luzuriaga, K. Absence of HIV-1 after treatment cessation in an infant. N. Engl. J. Med. 370, 678 (2014).
96. Santangelo, P.J. et al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat. Methods 12, 427-432 (2015).
97. + T cells. J. Infect. Dis. 208, 50-56 (2013).
98. + T cells during antiretroviral therapy. J. Virol. 88, 3516-3526 (2014).
99. + T-cells in HIV-infected individuals on antiretroviral therapy. AIDS (in the press).
100. van der Sluis, R.M. et al. Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment. AIDS 29, 1003-1014 (2015).
101. Tucker, J.D., Rennie, S. & Social and Ethical Working Group on HIV Cure. Social and ethical implications of HIV cure research. AIDS 28, 1247-1250 (2014).
102. Henderson, G.E. The ethics of HIV "cure" research: what can we learn from consent forms? AIDS Res. Hum. Retroviruses 31, 56-63 (2015).
103. Peay, H.L. & Henderson, G.E. What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J. Virus Erad. 1, 51-53 (2015).
104. Moodley, K., Staunton, C., de Roubaix, M. & Cotton, M. HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives. AIDS Care 28, 524-527 (2016).
105. Chu, C.E. et al. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res. Hum. Retroviruses 31, 78-84 (2015).
106. Lo, Y.R., Chu, C., Ananworanich, J., Excler, J.L. & Tucker, J.D. Stakeholder engagement in HIV cure research: Lessons learned from other HIV interventions and the way forward. AIDS Patient Care STDS 29, 389-399 (2015).
107. Newman, P.A. & Rubincam, C. Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence. Expert Rev. Vaccines 13, 1553-1562 (2014).
108. Sax, P.E. et al. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One 9, e113031 (2014).
109. Freedberg, K.A. et al. The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. J. Virus Erad. 1, 245-249 (2015).
110. Amon, J.J. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Global. Health 4, 5 (2008).
111. Yukl, S.A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).
112. Fauci, A.S., Marston, H.D. & Folkers, G.K. An HIV cure: feasibility, discovery, and implementation. J. Am. Med. Assoc. 312, 335-336 (2014).
113. Tucker, J.D., Volberding, P.A., Margolis, D.M., Rennie, S. & Barré-Sinoussi, F. Words matter: Discussing research towards an HIV cure in research and clinical contexts. J. Acquir. Immune Defic. Syndr. 67, e110-e111 (2014).
114. Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835 (2013).
115. Denton, P.W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630-634 (2012).
116. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
117. + cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. USA 109, 9523-9528 (2012).
118. Hurst, J. et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat. Commun. 6, 8495 (2015).
119. Assoumou, L. et al. ANRS 116 SALTO study group. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 29, 2003-2007 (2015).
120. Katlama, C. et al. EraMune-01 study team. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 30, 221-230 (2016).
121. Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51-56 (2016).
122. Wightman, F. et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27, 2853-2862 (2013).
123. Jiang, G. et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS 28, 1555-1566 (2014).
124. Boehm, D. et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452-462 (2013).
125. Rasmussen, T.A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13-e21 (2014).
126. Hansen, S.G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).